Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
GAITHERSBURG, Md., March 30, 2016 -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in Needham & Company’s 15th Annual Healthcare Conference, April 12-13, 2016 in New York, NY.
Presentation date and time will be updated on the Emergent website www.emergentbiosolutions.com under “Investors” as this information becomes available.
For this conference, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcast will be available both live and by replay, accessible from the Emergent website www.emergentbiosolutions.com under “Investors.”
About Emergent BioSolutions Inc.
Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3394 [email protected]
